Clinical management of rapidly growing mycobacterial cutaneous infections in patients after mesotherapy

Clinical Infectious Diseases

Volumn 49, Issue 9, 2009, Pages 1358-1364

  Regnier, Stéphanie ^a,d   Cambau, Emmanuelle ^c   Meningaud, Jean Paul ^c   Guihot, Amelie ^a   Deforges, Lionel ^c   Carbonne, Anne ^b   Bricaire, François ^a   Caumes, Eric ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b Regional Centre for Nosocomial Infection Control   (France)

^c HENRI MONDOR HOSPITAL   (France)

^d SAINT LOUIS HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CIPROFLOXACIN; CLARITHROMYCIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TIGECYCLINE; TOBRAMYCIN;

ABSCESS DRAINAGE; ADULT; ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM IDENTIFICATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE DURATION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ESTHETIC SURGERY; FEMALE; FOLLOW UP; HUMAN; LIVER CYTOLYSIS; LIVER DISEASE; MALE; MICROBIOLOGICAL EXAMINATION; MYALGIA; MYCOBACTERIAL CUTANEOUS INFECTION; MYCOBACTERIUM CHELONEI; NAUSEA; PATIENT CARE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RECURRENT INFECTION; SKIN EXAMINATION; SKIN INFECTION; TENDINITIS; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADULT; ANTI-BACTERIAL AGENTS; CLARITHROMYCIN; COSMETIC TECHNIQUES; FEMALE; HUMANS; MALE; MIDDLE AGED; MYCOBACTERIUM CHELONAE; MYCOBACTERIUM INFECTIONS; SKIN DISEASES, BACTERIAL; SUBCUTANEOUS FAT; YOUNG ADULT;

EID: 72849134707     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/606050     Document Type: Article

References (24)

1. Matarasso A, Pfeifer TM. Mesotherapy for body contouring. Plast Reconstr Surg 2005; 115:1420-1424
2. Meyers H, Brown-Elliott BA, Moore D, et al. An outbreak of Mycobacterium chelonae infection following liposuction. Clin Infect Dis 2002; 34: 1500-1507
3. . Macadam SA, Mehling BM, Fanning A, et al. Nontuberculous mycobacterial breast implant infections. Plast Reconstr Surg 2007; 119:337-344 (Pubitemid 46360283) (Pubitemid 46360283)
4. Finucane K, Ambrey P, Narayan S, et al. Insulin injection abscesses caused by Mycobacterium chelonae. Diabetes Care 2003; 26:2483-2484
5. Woo PC, Li JH, Tang W, Yuen K. Acupuncture mycobacteriosis. N Engl J Med 2001; 345:842-843
6. Garcia-Navarro X, Barnadas MA, Dalmau J, et al. Mycobacterium abscessus infection secondary to mesotherapy. Clin Exp Dermatol 2008; 33:658-659
7. Carbonne A, Brossier F, Arnaud I, et al. Outbreak of nontuberculous Mycobacteria subcutaneous infections related to multiple mesotherapy injections. J Clin Microbiol 2009; 47:1961-1964
8. Brown-Elliott BA,Wallace RJ Jr. Clinical and taxonomic status of pathogenic nonpigmented or late-pigmenting rapidly growing mycobacteria. Clin Microbiol Rev 2002; 15:716-746
9. Falkinham JO 3rd. Epidemiology of infection by nontuberculous mycobacteria. Clin Microbiol Rev 1996; 9:177-215.
10. Freitas D, Alvarenga L, Sampaio J, et al. An outbreak of Mycobacterium chelonae infection after LASIK. Ophthalmology 2003; 110:276-285
11. Munayco CV, Grijalva CG, Culqui DR, et al. Outbreak of persistent cutaneous abscesses due to Mycobacterium chelonae after mesotherapy sessions, Lima, Peru. Rev Saude Publica 2008; 42:146-149
12. Vijayaraghavan R, Chandrashekhar R, Sujatha Y, Belagavi CS. Hospital outbreak of atypical mycobacterial infection of port sites after laparoscopic surgery. J Hosp Infect 2006; 64:344-347 (Pubitemid 44661046) (Pubitemid 44661046)
13. Centers for Disease Control and Prevention. Follow-up on mycobacterial contamination of porcine heart valve prosthesis. MMWR Morb Mortal Wkly Rep 1978; 27:97-98
14. Swenson JM, Wallace RJ Jr, Silcox VA, Thornsberry C. Antimicrobial susceptibility of five subgroups of Mycobacterium fortuitum and Mycobacterium chelonae. Antimicrob Agents Chemother 1985; 28:807-811
15. Brown BA,Wallace RJ Jr, Onyi GO, De Rosas V,Wallace RJ 3rd. Activities of four macrolides, including clarithromycin, against Mycobacterium fortuitum, Mycobacterium chelonae, and M. chelonae-like organisms. Antimicrob Agents Chemother 1992; 36:180-184
16. Wallace RJ Jr, Brown-Elliott BA, Ward SC, et al. Activities of linezolid against rapidly growing mycobacteria. Antimicrob Agents Chemother 2001; 45:764-767 (Pubitemid 32182022) (Pubitemid 32182022)
17. Wallace RJ Jr, Brown BA, Onyi GO. Susceptibilities of Mycobacterium fortuitum biovar. fortuitum and the two subgroups of Mycobacterium chelonae to imipenem, cefmetazole, cefoxitin, and amoxicillin-clavulanic acid. Antimicrob Agents Chemother 1991; 35:773-775
18. Wallace RJ Jr, Brown-Elliott BA, Crist CJ, et al. Comparison of the in vitro activity of the glycylcycline tigecycline (formerly GAR-936) with those of tetracycline, minocycline, and doxycycline against isolates of nontuberculous mycobacteria. Antimicrob Agents Chemother 2002; 46:3164-3167
19. Brown-Elliott BA, Wallace RJ Jr, Crist CJ, et al. Comparison of in vitro activities of gatifloxacin and ciprofloxacin against four taxa of rapidly growing mycobacteria. Antimicrob Agents Chemother 2002; 46:3283-3285
20. Peres E, Khaled Y, Krijanovski OI, Mineishi S, et al. Mycobacterium chelonae necrotizing pneumonia after allogeneic hematopoietic stem cell transplant: report of clinical response to treatment with tigecycline. Transpl Infect Dis 2009; 11:57-63.
21. Wallace RJ Jr, Tanner D, Brennan PJ, Brown BA. Clinical trial of clarithromycin for cutaneous (disseminated) infection due to Mycobacterium chelonae. Ann Intern Med 1993; 119:482-486
22. Tebas P, Sultan F, Wallace RJ Jr, Fraser V. Rapid development of resistance to clarithromycin following monotherapy for disseminated Mycobacterium chelonae infection in a heart transplant patient. Clin Infect Dis 1995; 20:443-444
23. Medical Section of the American Lung Association. Diagnosis and treatment of disease caused by nontuberculous mycobacteria. Am J Respir Crit Care Med 1997; 156:S1-25.
24. Gorwitz RJ. The role of ancillary antimicrobial therapy for treatment of uncomplicated skin infections in the era of community-associated methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2007; 44: 785-787.